First Monopoly Agreement (January 2020): coordinated price in Shandong Province 14 January 2020: Shanghai Xinyi proposed setting its NMI price at RMB 79.33 per unit (2ml, 1mg) in Shandong Province. Initial price coordination Henan Runhong and Chengdu Huixin followed Shanghai Xinyi's lead. 17 January 2020: Shanghai Xinyi lowered its price to RMB 71.5/unit after realising it was priced higher than its competitors. Further price alignment The final NMI listing prices in Shandong Province became: Shanghai Xinyi: RMB 71.5/unit (2ml, 1mg) Henan Runhong: RMB 36/unit (1ml, 0.5mg) Chengdu Huixin: RMB 35.8/unit (1ml, 0.5mg) These coordinated actions aligned the Parties' pricing strategies in the market. Second Monopoly Agreement (March 2020): nationwide price fixing and market allocation 19 March 2020: **Price fixing:** agreed to increase nationwide NMI prices, and aligned provincial listing prices and hospital-negotiated prices Comprehensive with Shandong Province rates. collusive strategies Market allocation: (1) Private hospital market: Chengdu Huixin granted Shanghai Xinyi exclusive distribution rights to sell its NMI products to private hospitals, and set a predetermined annual sales target. (2) Public hospital market: Shanghai Xinyi and Henan Runhong agreed to share the public hospital market by: Sharing a single provincial distributor per province Maintaining existing hospital networks without competing Collaborating on expanding into new markets Additionally, Shanghai Xinyi and Henan Runhong – who operated in the public hospital market, which accounts for 97% of NMI product sales – provided financial compensation to Chengdu Huixin, which

agreed to sell its products primarily to private hospitals (instead of public hospitals) through Shanghai Xinyi during the scheme, to ensure the implementation of the Second Monopoly Agreement.